Neuropsychiatry

Mar
08

Moving the Needle in Bipolar I Depression: Novel Strategies to Improve Patient Outcomes

Bipolar I depression is a serious, debilitating disorder, and the challenge of management is compounded by the limited treatment options that are available. Current D2-targeted strategies to manage bipolar depression are limited in their effectiveness, as these approaches do not specifically target the neurobiology of the disease. Data is emerging that demonstrates that the novel […]

Read More
By Simone Kahmeyer |
DETAIL
Mar
08

From Bench to Bedside: Novel Strategies Addressing the Negative Symptoms of Schizophrenia to Improve Clinical and Functional Outcomes

Schizophrenia is a chronic and debilitating disease, and pharmacotherapy for it has focused on the management of positive symptoms using atypical antipsychotics, leading to negative symptoms that contributed more to impaired quality of life being left untreated or underrated. Due to the persistent and chronic nature of negative symptoms, the need for effective therapy with […]

Read More
By Simone Kahmeyer |
DETAIL
Mar
08

Moving Beyond “Better” to Getting Patients “Well”: Tools to Measure How “Well” Your Patient is Doing with Treatment

Primary care has become the point-of-care where most people seek treatment for depression, and effort to improve depression outcomes in primary care have focused on improved screening and implementation of collaborative and measurement-based care. However, a recent study showed that only 35.7% of patients diagnosed with depression had treatment initiated, despite the demonstrated value of […]

Read More
By Simone Kahmeyer |
DETAIL
Mar
08

Routine Screening for Depression Like We Screen for Hypertension

Depression is a common, debilitating disorder affecting 12.8% of adolescents and 6.7% of adults in the United States. Routine depression screening is critical to ensure opportunities are not missed to provide patient treatment. The role of primary care in screening, detection, and treatment of depression has grown, becoming the point-of-care where most people seek treatment. […]

Read More
By Simone Kahmeyer |
DETAIL
Mar
08

Recent Clinical Trial Data on the Safety and Efficacy of Current and Emerging Therapies to Optimize Schizophrenia Management

Safe and effective treatments for schizophrenia are imperative to optimizing personalized therapy, which helps in reducing relapse and promoting functional recovery in patients with schizophrenia. Emerging data on reducing symptoms, maintaining effective therapy over long-term periods, and minimizing treatment-related metabolic side effects can guide clinicians in choosing the best therapies for their patients. In the […]

Read More
By Simone Kahmeyer |
DETAIL
Mar
08

Current and Emerging Therapies for Schizophrenia: How MOA Affects Clinical Outcomes

Clinical trial data that addresses the safety and efficacy of antipsychotics is continuously emerging, with a focus on optimizing the management of schizophrenia. These data include the identification of strategies with novel mechanisms of action (MOAs) to effectively resolve symptoms and promote recovery while minimizing metabolic effects. The second episode of this schizophrenia CMEOcast podcast […]

Read More
By Simone Kahmeyer |
DETAIL
Mar
08

Long-Acting Injectables: An Effective, Yet Often Underutilized Tool for Rapid Symptom Reduction and Restoration of Function

Schizophrenia is a serious and debilitating disorder that often poses a considerable challenge to clinicians. While long-acting injectables (LAIs) have emerged as a viable means to address patient nonadherence – often a component of schizophrenia management – clinicians often fail to implement the use of LAIs. Many times this is due to clinicians not being […]

Read More
By Simone Kahmeyer |
DETAIL